Related Experiment Videos
Renal insufficiency after heart transplantation: a case-control study
T van Gelder1, A H Balk, R Zietse
1Department of Internal Medicine I, University Hospital Rotterdam-Dijkzigt, The Netherlands.
Summary
End-stage renal failure is a long-term risk after heart transplantation, often linked to cyclosporine. This risk affects various patient groups, suggesting individual susceptibility plays a key role.
Area of Science:
- Cardiology
- Nephrology
- Transplantation Medicine
Background:
- 8% of 304 heart transplant recipients developed end-stage renal failure (ESRF) 25-121 months post-transplant.
- One-year survival after initiating renal replacement therapy was 60% for these patients.
- Overall heart transplant survival remains favorable: 5-year (79%) and 10-year (50%) rates.
Purpose of the Study:
- To identify risk factors for ESRF post-heart transplantation.
- To compare patients who developed ESRF with those who did not.
Main Methods:
- A case-control study design was employed.
- Cases were patients who developed ESRF after heart transplantation.
- Controls were heart transplant recipients who did not develop ESRF.
Main Results:
- ESRF occurred in both elderly patients with ischemic heart disease and younger patients with dilated cardiomyopathy.
- A significant increase in serum creatinine was observed in cases by 3 months post-transplant.
- No significant differences were found in cyclosporine doses/levels, antihypertensive use, allopurinol, diuretics, or rejection incidence between cases and controls.
Conclusions:
- Renal failure is a long-term complication of cyclosporine use following heart transplantation.
- This complication is not exclusive to elderly patients with ischemic heart disease.
- Individual susceptibility to cyclosporine appears to be a primary driver of nephrotoxicity, necessitating preventative strategies.